CLD

Calidi

Stock
Stock
Ticker: CLDI
CLDI

Price

Price

CHART BY

Frequently asked questions

The market capitalization of Calidi is $2.79M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
Calidi's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$54.07. EPS indicates the company's profitability on a per-share basis.
Currently, 1 analysts cover Calidi's stock, with a consensus target price of $1,920.00. Analyst ratings provide insights into the stock's expected performance.
Calidi's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$16.14M. EBITDA measures the company's overall financial performance.
Calidi has a free cash flow of -$17.85M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
Calidi employs approximately 29 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
The free float of Calidi is 2.56M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap 
$2.79M
EPS (TTM) 
-$54.07
Free Float 
2.56M
EBITDA (TTM) 
-$16.14M
Free Cashflow (TTM) 
-$17.85M

Pricing

52W span
$1.03$27.36

Analyst Ratings

The price target is $1,920.00 and the stock is covered by 1 analysts.

Buy

1

Hold

0

Sell

0

Information

Calidi Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in stem cell-based platforms to revolutionize oncolytic virotherapies. The company was founded in 2014 and is headquartered in San Diego, CA.

Employees
29
Industries
Biotechnology
Sector
Health Care

Identifier

Primary Ticker
CLDI
Fundamentals & EOD data from FactSet
Join the conversation